2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Lymphoma, Non-Hodgkin
4
Leukemia, Myeloid, Acute
4
Leukemia
4
Colonic Neoplasms
4
Congenital Abnormalities
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Waldenstrom Macroglobulinemia
2
Somatostatinoma
2
Recurrence
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms
2
Myeloproliferative Disorders
2
Multiple Myeloma
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma
2
Lung Neoplasms
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Monocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Colorectal Neoplasms
2
Carcinoma, Islet Cell
2
Vulvar Neoplasms
1
Vipoma
1
Vaginal Neoplasms
1
Interventions
Gemcitabine
40
Cisplatin
24
Capecitabine
21
Fluorouracil
19
Oxaliplatin
17
Leucovorin
14
pembrolizumab
9
Irinotecan
8
Radiotherapy
7
Erlotinib Hydrochloride
7
durvalumab
6
Sorafenib
4
Photochemotherapy
4
Magnetic Resonance Spectroscopy
4
Carboplatin
4
trametinib
3
Trastuzumab
3
Radiofrequency Ablation
3
Long-Term Synaptic Depression
3
Interleukin-12 Subunit p35
3
Filgrastim
3
Drug Therapy
3
Dihematoporphyrin Ether
3
Dexamethasone
3
Cholangiopancreatography, Endoscopic Retrograde
3
Chemotherapy, Adjuvant
3
trifluridine tipiracil drug combination
2
tivozanib
2
tislelizumab
2
spartalizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bile Duct Neoplasms
×
Biological Therapy
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled